NCT02144714View on ClinicalTrials.gov

Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Healthy
Interventions
BIOLOGICAL

SB5

BIOLOGICAL

EU sourced Humira®

BIOLOGICAL

US sourced Humira®

Trial Locations (1)

Unknown

Samsung Investigational Site, Berlin

All Listed Sponsors
lead

Samsung Bioepis Co., Ltd.

INDUSTRY

NCT02144714 - Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy Subjects | Biotech Hunter | Biotech Hunter